Why Semaglutide is an inflection point for India’s generics sector?

More than a supply chain issue and missing the first mover status, Semaglutide episode has rather exposed systemic chinks and could prove costly for India’s pharmaceutical industry, which supplies about 20% of the world’s generic medicines by volume.

from Industry News, Company News, Manufacturing News, Service Sector | The Hindu https://ift.tt/VoAFn0a